Atlas Trials

Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors

Clinical trial NCT05441046 · UNKNOWN

Trial details

NCT number
NCT05441046
Sponsor
Changchun GeneScience Pharmaceutical Co., Ltd.
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
Malignant Solid Tumors
Start date
2022-06-07
Primary completion
2024-06-01
Enrollment
120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.